Century Therapeutics, Inc. Revenue
Century Therapeutics, Inc. (IPSC) reported Revenue of $109.16 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · last filed 2026-08-12
- Century Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-06-30 was $0.00, a 100.00% decline year-over-year.
- Century Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for the quarter ending 2025-03-31 was $109.16M, a 12667.72% increase year-over-year.
- Century Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2025 was $109.16M, a 1556.76% increase from fiscal 2024.
- Century Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2024 was $6.59M, a 194.81% increase from fiscal 2023.
- Century Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2023 was $2.23M, a 57.01% decline from fiscal 2022.
- Century Therapeutics, Inc. revenue from contract with customer, excluding assessed tax for fiscal 2022 was $5.20M.
| Period end | Revenue from Contract with Customer, Excluding Assessed Tax 3 month | Revenue from Contract with Customer, Excluding Assessed Tax 6 month | Revenue from Contract with Customer, Excluding Assessed Tax 9 month | Revenue from Contract with Customer, Excluding Assessed Tax 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $0.00 derived: sum of 2 quarters · filed 2026-03-12 | $0.00 derived: sum of 3 quarters · filed 2026-08-12 | $109.16M 10-K · filed 2026-03-12 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-12 | $109.16M 10-Q · filed 2025-11-13 | $113.34M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $109.16M 10-Q · filed 2026-08-12 | $113.34M derived: sum of 3 quarters · filed 2026-08-12 | $114.13M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $109.16M 10-Q · filed 2026-05-13 | $113.34M derived: sum of 2 quarters · filed 2026-05-13 | $114.13M derived: sum of 3 quarters · filed 2026-05-13 | $114.90M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $4.17M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.96M derived: sum of 2 quarters · filed 2026-03-12 | $5.74M derived: sum of 3 quarters · filed 2026-03-12 | $6.59M 10-K · filed 2026-03-12 |
| 2024-09-30 | $791.00K 10-Q · filed 2025-11-13 | $1.56M derived: sum of 2 quarters · filed 2025-11-13 | $2.42M 10-Q · filed 2025-11-13 | $2.69M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $771.00K 10-Q · filed 2025-08-14 | $1.63M 10-Q · filed 2025-08-14 | $1.89M derived: sum of 3 quarters · filed 2025-08-14 | $2.04M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $855.00K 10-Q · filed 2025-05-15 | $1.12M derived: sum of 2 quarters · filed 2025-05-15 | $1.27M derived: sum of 3 quarters · filed 2025-05-15 | $1.37M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $268.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $416.00K derived: sum of 2 quarters · filed 2025-03-19 | $515.00K derived: sum of 3 quarters · filed 2025-03-19 | $2.23M 10-K · filed 2025-03-19 |
| 2023-09-30 | $148.00K 10-Q · filed 2024-11-05 | $247.00K derived: sum of 2 quarters · filed 2024-11-05 | $1.97M 10-Q · filed 2024-11-05 | $2.49M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $99.00K 10-Q · filed 2024-08-08 | $1.82M 10-Q · filed 2024-08-08 | $2.34M derived: sum of 3 quarters · filed 2024-08-08 | $4.56M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $1.72M 10-Q · filed 2024-05-09 | $2.24M derived: sum of 2 quarters · filed 2024-05-09 | $4.46M derived: sum of 3 quarters · filed 2024-05-09 | $5.86M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $521.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.75M derived: sum of 2 quarters · filed 2024-03-14 | $4.14M derived: sum of 3 quarters · filed 2024-03-14 | $5.20M 10-K · filed 2024-03-14 |
| 2022-09-30 | $2.22M 10-Q · filed 2023-11-09 | $3.62M derived: sum of 2 quarters · filed 2023-11-09 | $4.68M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $1.40M 10-Q · filed 2023-08-09 | $2.45M 10-Q · filed 2023-08-09 | ||
| 2022-03-31 | $1.06M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |